Psyence Biomedical Ltd. carries no debt; cash flow comfortably covers obligations.

Psyence Biomedical Ltd.'s free cash flow has decreased 130.85% from $-3.74M last year to $-8.64M, signaling decreasing performance

Psyence Biomedical Ltd.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Psyence Biomedical Ltd. has insufficient data to evaluate this check.

Psyence Biomedical Ltd. has a net cash position, so leverage is healthy.

Psyence Biomedical Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Psyence Biomedical Ltd. has insufficient data to evaluate this check.

Psyence Biomedical Ltd.'s short-term assets of $9.11M exceed its short-term liabilities of $623.19K

Psyence Biomedical Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Psyence Biomedical Ltd.'s return on equity of -58.62%, is lower than 15.00%, indicating bad performance

Psyence Biomedical Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Psyence Biomedical Ltd. has insufficient public price history to evaluate earnings stability.

Psyence Biomedical Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Psyence Biomedical Ltd. has negative free cash flow, indicating cash burn

Psyence Biomedical Ltd.'s yearly earnings has decreased 785.56% since last year from $1.01M to $-6.94M, signaling decreasing performance

Psyence Biomedical Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -36.81% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Psyence Biomedical Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.

Psyence Biomedical Ltd. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Psyence Biomedical Ltd. has insufficient public price history to evaluate ROE consistency.

Psyence Biomedical Ltd. has insufficient data to evaluate this check.

Psyence Biomedical Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Psyence Biomedical Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Psyence Biomedical Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Psyence Biomedical Ltd. has insufficient data to evaluate this check.

Psyence Biomedical Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Psyence Biomedical Ltd. has negative shareholder equity; price-to-book is not meaningful and the check fails

Psyence Biomedical Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue